Impact of Coffeeberry Extract on Skill Performance During Simulated Match Play in Academy Football Players

Sponsor
PepsiCo Global R&D (Industry)
Overall Status
Recruiting
CT.gov ID
NCT05547204
Collaborator
(none)
15
1
2
7.1
2.1

Study Details

Study Description

Brief Summary

This study of soccer skill performance has three objectives:
  1. Compare effects of coffeeberry (300mg) and placebo ingestion on dribbling speed and precision, passing speed and accuracy, and sprint speed during a full simulated soccer match.

  2. Compare effects of coffeeberry (300mg) and placebo ingestion on subjective measures (mental / physical energy and activation-deactivation (feelings or mood) during a full simulated soccer match.

  3. Compare effects of coffeeberry (300mg) and placebo ingestion on chlorogenic acid (CGA) and caffeine metabolites in the blood 1-hour post ingestion, and other blood metabolites (glucose/lactate) throughout the simulated soccer match.

Condition or Disease Intervention/Treatment Phase
  • Other: Beverage
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
15 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Basic Science
Official Title:
Impact of Coffeeberry Extract on Skill Performance During Simulated Match Play in Academy Football Players.
Actual Study Start Date :
Jun 30, 2022
Anticipated Primary Completion Date :
Jan 31, 2023
Anticipated Study Completion Date :
Jan 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Coffeeberry beverage

300 ml drink containing 300 mg coffeeberry extract

Other: Beverage
Free from added carbohydrates (contain 1g CHO only) and electrolytes are absent.

Placebo Comparator: Color and flavor matched beverage

300 ml drink (0 mg coffeeberry extract, 0 mg caffeine)

Other: Beverage
Free from added carbohydrates (contain 1g CHO only) and electrolytes are absent.

Outcome Measures

Primary Outcome Measures

  1. Dribbling speed [Change from pre-dose baseline through end of match 3.5 hours post consumption at multiple intervals each half of match]

    m/sec, increase would be better. Simulated soccer match in an indoor gym with pre-set targets.

  2. Dribbling precision [Change from pre-dose baseline through end of match 3.5 hours post consumption at multiple intervals each half of match]

    Meters, more accuracy would be better. Simulated soccer match in an indoor gym with pre-set targets.

  3. Passing accuracy [Change from pre-dose baseline through end of match 3.5 hours post consumption at multiple intervals each half of match]

    1-10 scale, higher score would be better. Simulated soccer match in an indoor gym with pre-set targets.

  4. Passing speed [Change from pre-dose baseline through end of match 3.5 hours post consumption at multiple intervals each half of match]

    km/h, increased would be better. Simulated soccer match in an indoor gym with pre-set targets.

  5. Sprint speed. [Change from pre-dose baseline through end of match 3.5 hours post consumption at multiple intervals each half of match]

    m/sec, increase would be better. In indoor gym with marked course.

Secondary Outcome Measures

  1. Blood analyte: Chlorogenic acid (CGA) [Pre-dose baseline, 60 minutes post-dose, half-time, and end of match (3.5 hours)]

    mmol/L to evaluate primary outcomes. n.a. for placebo. Capillary blood draw for frozen plasma analysis

  2. Blood analyte: Caffeine metabolites [Pre-dose baseline, 60 minutes post-dose, half-time, and end of match (3.5 hours)]

    ug/ml, to evaluate primary outcomes. n.a. for placebo. Capillary blood draw for frozen plasma analysis

  3. Blood analyte: Glucose [Pre-dose baseline, 60 minutes post-dose, half-time, and end of match (3.5 hours)]

    mmol/L, more regulated would be better. Capillary blood draw for frozen plasma analysis

  4. Blood analyte: Lactate [Pre-dose baseline, 60 minutes post-dose, half-time, and end of match (3.5 hours)]

    mmol/L, lower (delayed rise) would be better. Capillary blood draw for frozen plasma analysis

  5. Rating of perceived exertion (RPE) [Half-time and end of match (3.5 hours)]

    By Borg scale, rated 6-20, very very light to very very hard. Lower values would be better

  6. Activation-deactivation (feelings or mood) [Pre-dose baseline, 60 minutes post-dose, half-time, and end of match (3.5 hours)]

    Checklist of 20 feelings using a 4 point scale from definitely do feel to definitely don't feel. More relaxed and better mood would be better.

  7. Mental energy [Pre-dose baseline, 60 minutes post-dose, half-time, and end of match (3.5 hours)]

    Visual Analog Scale (VAS), vertical marking on 100 mm horizontal line. Higher energy would be better

  8. Physical energy [Pre-dose baseline, 60 minutes post-dose, half-time, and end of match (3.5 hours)]

    Visual Analog Scale (VAS), vertical marking on 100 mm horizontal line. Higher energy would be better

  9. Gut comfort [Pre-dose baseline, 60 minutes post-dose, half-time, and end of match (3.5 hours)]

    Visual Analog Scale (VAS), vertical marking on 100 mm horizontal line. No or less nausea, fullness or bloating would be better

  10. Heart rate [Continuous from pre-dose baseline through end of match (3.5 hours)]

    By electronic reading. Lower would be better.

  11. Hydration status [Pre-dose baseline and end of match (3.5 hours)]

    Urine osmolality in mOsm/kg change in concentration pre- vs. post-exercise

Eligibility Criteria

Criteria

Ages Eligible for Study:
16 Years to 28 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Provide valid informed consent prior to any study procedure

  • Male soccer players age 16 to 28 years.

  • = 5-year soccer playing experience

  • = 1-year regularly soccer training

  • Free of injuries

  • Willing to avoid alcohol in the 48-h period prior to all visits

  • Willing to avoid caffeinated products and apples, berries/cherries for 24-h prior to all visits

  • Willing to record food intake over the 48-h period prior to the first trial and replicate for second trial

  • Willing to abstain from strenuous physical activity for 24-h before all visits

Exclusion Criteria:
  • Smoking

  • Cardiovascular diseases

  • Diabetes or other metabolic disease • Hypertension (>140/>90 mm Hg)

  • Presence of injuries

  • Major illnesses or surgery in prior 90 days

  • Participation in another clinical trial in the past month

Contacts and Locations

Locations

Site City State Country Postal Code
1 U. Stirling, Health Science and Sport Stirling Scotland United Kingdom FK9 4LA

Sponsors and Collaborators

  • PepsiCo Global R&D

Investigators

  • Principal Investigator: Stuart Galloway, PhD, U. Stirling, Scotland

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
PepsiCo Global R&D
ClinicalTrials.gov Identifier:
NCT05547204
Other Study ID Numbers:
  • PEP-2114
First Posted:
Sep 21, 2022
Last Update Posted:
Sep 21, 2022
Last Verified:
Sep 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by PepsiCo Global R&D

Study Results

No Results Posted as of Sep 21, 2022